deCode Genetics

Executive Summary

deCode Genetics, a subsidiary of Amgen based in Reykjavik, Iceland, is a pioneer in human genetics and genomics. Since its founding in 1996, it has leveraged Iceland's unique population resources to build one of the world's most extensive genetic databases, enabling the discovery of disease-associated variants and drug targets. Under Amgen's ownership, deCode integrates its genetic insights into Amgen's drug development pipeline, driving progress in precision medicine. The company's large-scale sequencing efforts and bioinformatics capabilities facilitate the identification of novel therapeutic targets and biomarkers, contributing to Amgen's R&D productivity. deCode's work has been instrumental in advancing understanding of common and rare diseases, and it continues to expand its impact through partnerships and data-sharing initiatives. As a wholly owned subsidiary, deCode benefits from Amgen's resources while maintaining its focus on cutting-edge genomic research.

Upcoming Catalysts (preview)

• Q4 2026Release of new population-scale whole genome sequencing data80% success
• Q2 2027Expansion of CRISPR-based target validation collaboration with Amgen60% success
• Q1 2027FDA approval of a drug informed by deCODE genetics findings40% success